APRE News and Press, Aprea Therapeutics Inc. From 03/31/23

2023-03-31 00:49:09 ET Aprea Therapeutics press release ( NASDAQ: APRE ): Q4 GAAP EPS of -$0.92 beats by $2.30 . As of December 31, 2022, the Company reported cash and cash equivalents of $28.8 million compared to $53.1 million as of December 31, 2021. The Company beli...

DOYLESTOWN, Pa., March 30, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage respo...

DOYLESTOWN, Pa., March 16, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathw...

DOYLESTOWN, Pa., March 07, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathw...

Aprea Therapeutics ( NASDAQ: APRE ) received formal notice from The Nasdaq Stock Market that it has regained compliance with its minimum bid price for continued listing on the Nasdaq Global Select Market. "We are excited about regaining compliance and we believe our ...

DOYLESTOWN, Pa., March 01, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathw...

DOYLESTOWN, Pa., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, t...

Aprea Therapeutics ( NASDAQ: APRE ) shares fell over 17% in Wednesday's extended trading after the biopharmaceutical company priced its $5.5M stock offering. The offering comprises 1,050,000 shares of its common stock issued at a price of $5.25/share. In addition, the underwri...

DOYLESTOWN, Pa., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, t...

Aprea Therapeutics ( NASDAQ: APRE ) said Wednesday it has commenced an underwritten public offering of shares of its common stock. All shares of common stock in the offering are to be sold by Aprea. Aprea also intends to grant the underwriter in the offering a 30-day optio...